Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib for PIK3CA-mutated lymphatic malformations
NL-OMON60626Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lymphangioma comparing Alpelisib with Placebo (2 arms). Started Jan 2026; status: recruiting.
02
Drugs
alpelisib
03
Conditions
lymphangioma
Beyond the preview
Go deeper on NL-OMON60626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60626.